Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs.
Eight sublines of the radiation-induced lymphoma S-1033 of C57BL/10 (hereafter called B10) origin were established by exposing the cells in vivo to eight antineoplastic agents for a number of transplant generations. The parental and drug-treated sublines were tested for immunogenic properties, i.e., the ability to elicit allograft reactions in the host of origin and in congenic-resistant mice differing for the S-D or K-I-S regions of the H-2 complex. Lymphoma S-1033 and all drug-treated sublines except one were found to be essentially nonimmunogenic for B10 mice. The S-DIC subline, when exposed for 8 to 12 transplant generations to dimethyltriazenoimidazolecarboxamide, became immunogenic for syngeneic B10 mice, as judged from prolongation of survival time. Large i.v. inocula (10(7) cells) of S-1033 and of the drug-treated sublines, with the possible exception of the cyclophosphamide-treated and dimethyltriazenoimideazolecarboxamide-treated lymphomas, were more effectively rejected by K-I-S- than by S-D-incompatible mice. Dilution escape (i.e., tumor rejection after challenge with large inocula, and lethal tumor growth after injection of small inocula of lymphoma cells in allogeneic recipients) occurred in K-I-S-incompatible mice that were inoculated with S-1033 and three drug-treated (5-fluorouracil, cyclophosphamide, and pyrazocarboxamideamino) sublines. No dilution escape occurred with dimethyltriazenoimidazolecarboxamide or bischloroethylnitrosourea sublines. These data favor the hypothesis that various types of immunogenic changes of neoplastic cells may occur in tumor-bearing hosts following treatment with antineoplastic agents in vivo.
D000818:Animals; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity; D003520:Cyclophosphamide / Q000494:pharmacology; D003606:Dacarbazine / Q000494:pharmacology; D005472:Fluorouracil / Q000494:pharmacology; D006649:Histocompatibility Antigens; D007109:Immunity / Q000187:drug effects; D008223:Lymphoma / Q000209:etiology / Q000276:immunology*; D008727:Methotrexate / Q000031:analogs & derivatives / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology; D009381:Neoplasms, Radiation-Induced / Q000276:immunology*; D009607:Nitrosourea Compounds / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D013866:Thioguanine / Q000494:pharmacology; D014181:Transplantation Immunology; D014184:Transplantation, Homologous; D014965:X-Rays
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D006649:Histocompatibility Antigens; D009607:Nitrosourea Compounds; D011720:Pyrazoles; D003606:Dacarbazine; D003520:Cyclophosphamide; D013866:Thioguanine; D005472:Fluorouracil; D008727:Methotrexate